Lennox-Gastaut%2525252525252525252525252520syndrome

# Lennox-Gastaut Syndrome (LGS) ## Overview LGS is a severe form of developmental and epileptic encephalopathy characterized by multiple seizure types, characteristic slow spike-and-wave EEG patterns, and cognitive impairment. Pharmacotherapy is typically adjunctive, as monotherapy is rarely effective. ## Primary Indications Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. Common agents include Clobazam, Rufinamide, Topiramate, Felbamate, Lamotrigine, and Cannabidiol (CBD). ## Adult Dosing * **Clobazam:** Start 5 mg/day; titrate to 20 mg/day (target dose). Max 40 mg/day. * **Rufinamide:** Start 400–800 mg/day in two divided doses; titrate by 400–800 mg every 2 days. Max 3,200 mg/day. * **Cannabidiol:** Start 2.5 mg/kg BID; titrate after 1 week to 5 mg/kg BID (10 mg/kg/day). Max 20 mg/kg/day. * **Topiramate:** Start 25 mg/day; titrate slowly to 200–400 mg/day in two divided doses. * **Felbamate:** Start 1,200 mg/day in 3–4 divided doses; titrate by 1,200 mg/week. Max 3,600 mg/day. ## Pediatric Dosing * **Clobazam (≥2 years):** Weight-based; <30 kg: 5 mg/day up to 20 mg/day; ≥30 kg: 10 mg/day up to 40 mg/day. * **Rufinamide (≥1 year):** Start 10 mg/kg/day (or 200 mg/day) in two doses; increase by 10 mg/kg/day every 2 days. Max 45 mg/kg/day or 3,200 mg/day. * **Cannabidiol (≥1 year):** 2.5 mg/kg BID; titrate to 5 mg/kg BID. Max 10–20 mg/kg/day. * **Topiramate (≥2 years):** Start 1–3 mg/kg/day; titrate slowly. Target dose 5–9 mg/kg/day. ## Dose Adjustments * **Renal/Hepatic:** Most anti-seizure medications (ASMs) require dose reduction in severe impairment. For **Rufinamide**, avoid in severe hepatic impairment. For **Felbamate**, baseline and recurring liver function testing (LFT) is mandatory. * **Cannabidiol:** Reduce dose in moderate-to-severe hepatic impairment (Child-Pugh A, B, C). ## Contraindications * **Felbamate:** History of hepatic failure or bone marrow suppression (Black Box Warning). * **Rufinamide:** Familial Short QT syndrome. * **Clobazam/Topiramate:** Known hypersensitivity. ## Adverse Effects * **Common:** Somnolence, fatigue, dizziness, gastrointestinal distress (diarrhea/nausea), appetite decrease, and ataxia. * **Specific:** **Felbamate** (aplastic anemia, hepatotoxicity); **Topiramate** (nephrolithiasis, metabolic acidosis, sweating/anhidrosis); **Cannabidiol** (elevated LFTs, diarrhea). ## Key Drug Interactions * **Clobazam:** CYP2C19 inhibitors (e.g., fluconazole, omeprazole) increase clobazam levels; monitor for sedation. * **Rufinamide:** Valproic acid significantly increases rufinamide levels; lower the rufinamide dose. * **Topiramate:** May decrease efficacy of oral contraceptives. * **Cannabidiol:** Increases levels of clobazam (via N-desmethylclobazam metabolite); may require clobazam dose reduction. ## Monitoring * **Baseline/Routine:** CBC, LFTs, and renal function. * **Specific:** For Topiramate, monitor bicarbonate/electrolytes. For Felbamate, perform LFTs and CBC every 1–2 weeks initially. For Cannabidiol, monitor LFTs at baseline, 2 weeks, 4 weeks, and 8 weeks. * **Neurological:** Monitor for changes in seizure frequency/type and signs of depression or suicidal ideation (Class-wide warning for ASMs). ## Clinical Pearls * **Polypharmacy:** Most patients require multiple agents; prioritize those with different mechanisms of action. * **Titration:** "Start low, go slow" is critical to minimize intolerable side effects like sedation and cognitive impairment. * **Valproic Acid:** Often used as a primary agent but strictly monitor drug-drug interactions, particularly with rufinamide and lamotrigine (rash risk). * **Individualization:** Always consult local hospital protocols, as institutional preference for first-line therapies varies. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical indications, drug dosing, and contraindicated combinations are subject to change. Always verify current prescribing information, institutional formulary guidelines, and patient-specific factors via professional drug databases (e.g., Lexicomp, Micromedex) before prescribing or administering medication.